Past Lexiva Treatment May Reduce Benefit From Prezista A recent study reported by AIDSmap has found that some people who have developed drug resistance to the protease inhibitor (PI) Lexiva (fosamprenavir) may have a reduced benefit from another PI, Prezista (darunavir).
September 27, 2007
Ban on European Viracept Sales Lifted The European Medicines Agency (EMEA) has announced that it is lifting its recent ban on the sale of Viracept (nelfinavir) in Europe, according to the Associated Press.
48-Week Selzentry Data Show Promise for Drug-Resistant HIV Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
Selzentry Treatment Failure: The Impact of Tropism Changes Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s.
HIV Prevalence Declines in Pregnant Women in Zimbabwe Of a new study presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago (ICAAC) this week, AIDSmap reports that the percentage of pregnant women who tested positive at a Zimbabwe hospital dropped by 41 percent between 1999 and 2007.
IL-2 May Delay Need for Antiretroviral Treatment An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high and postpone their need to begin antiretroviral therapy.
Heart Disease Risk Remains in Absence of HIV Treatment There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is.
High Risk of Peripheral Artery Disease in HIV Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.
Lexiva and Kaletra Comparable in Long-Term Study New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness.
Skin Test Predicts Control of HPV A new study shows that a simple skin-prick test may be useful in helping HIV-positive women determine if their immune systems are strong enough to control cancer-causing human papilloma virus (HPV) infection.
September 13, 2007
More Reports on Kidney Stones With Reyataz A French study, published in the September 12 issue of Clinical Infectious Diseases, mirrors another report from the United States suggesting that kidney stones may be a side effect of the protease inhibitor Reyataz.
HIV Damages Brain Despite Treatment HIV treatment may not fully protect the brain or eliminate the risk of impaired brain functioning, according to a new study published in the September issue of AIDS and reported today by AIDSmap.
September 10, 2007
High-Fat Diets Affect Disease Progression
Scientists have added another strike against high-fat diets. A recent animal study in the Journal of Infectious Diseases suggests that a diet high in saturated fat and cholesterol may accelerate HIV disease progression.
Isentress Recommended for FDA Approval
As widely reported yesterday, an advisory committee to the FDA has unanimously voted to recommend approval for Isentress—the first of a new class of antiviral drug known as an integrase inhibitor—for use in people who’ve developed resistance to other drugs.
September 05, 2007
Promising New Nuke, Apricitabine A new drug in development, apricitabine (ATC), may have moved another step closer toward inclusion in the arsenal of drugs approved to fight HIV.